Market Place

Market Place

Market Place

Menu

Post Enquiry

Post Enquiry

PharmaCompass

Home

Market Place

Market Place

Search
All
API
FDF
Price
Services
Excipients
Enquiries

    Find

    • Active Pharmaceutical Ingredients Active Pharmaceutical Ingredients
    • Finished Drug Formulations Finished Drug Formulations
    • Price Price
    • Excipients Excipients
    • Services Services
    • Market Place Marketplace

    Market Place

    Market Place

    Post Enquiry

    Post Enquiry
    Pipeline-Prospector-Insert
    X

    Find drug development pipeline and deal Updates information

    A collaboration with SCORR Marketing

    Loading...

    All Data

    Filters Filter refresh
    ×
    FILTER DATA :
    News Type filter
      Company filter
        Product Type filter
          Deal Size filter
            Upfront Payment filter
              refresh

              Product Type

              Companies

              Cellectis

              • Development Update

              Virtual Booth Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

              FRANCE France

              Post An Enquiry Post An Enquiry

              Virtual Booth Virtual Booth

              Annual Biomarkers Congress

              Participation Not Confirmed

              Request a Meeting Now

              First Patient Dosed with Cellectis’ New Allogeneic UCART123 Product Candidate for Relapsed/Refractory Acute Myeloid Leukemia

              Contact the Supplier

              Lead Product(s): UCART123

              Therapeutic Area: Oncology

              Highest Development Status: Phase I Product Type: Large molecule

              Partner/Sponsor/Collaborator: Not Applicable

              Deal Size: Not Applicable Upfront Cash: Not Applicable

              Deal Type: Not Applicable January 15, 2020

              Details:

              AMELI-01 clinical trial uses new UCART123 construct with optimized production process & new IND number.

              Invectys

              • Development Update

              Virtual Booth Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

              FRANCE France

              Post An Enquiry Post An Enquiry

              Virtual Booth Virtual Booth

              Annual Biomarkers Congress

              Participation Not Confirmed

              Request a Meeting Now

              Phase I clinical trial results published for Invectys DNA Vaccine for Cancer using PharmaJet Needle-free injector

              Contact the Supplier

              Lead Product(s): INVAC-1

              Therapeutic Area: Oncology

              Highest Development Status: Phase I Product Type: Vaccine

              Partner/Sponsor/Collaborator: Not Applicable

              Deal Size: Not Applicable Upfront Cash: Not Applicable

              Deal Type: Not Applicable January 08, 2020

              Details:

              This is the first in-human study of INVAC-1, an immune-therapeutic DNA vaccine for the treatment of cancer.

              Transgene

              • Development Update

              Virtual Booth Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

              FRANCE France

              Post An Enquiry Post An Enquiry

              Virtual Booth Virtual Booth

              Annual Biomarkers Congress

              Participation Not Confirmed

              Request a Meeting Now

              Transgene and NEC Start Two Clinical Trials with TG4050, an AI-Powered Cancer Vaccine for Ovarian and Head & Neck Cancers

              Contact the Supplier

              Lead Product(s): TG4050

              Therapeutic Area: Oncology

              Highest Development Status: Phase I Product Type: Vaccine

              Partner/Sponsor/Collaborator: Not Applicable

              Deal Size: Not Applicable Upfront Cash: Not Applicable

              Deal Type: Not Applicable January 06, 2020

              Details:

              TG4050 moves therapeutic vaccination into the digital age: combines Transgene’s expertise in viral vectors with NEC’s cutting-edge Artificial Intelligence (AI) capabilities.

              PharmaCompass__DigitalAd